Biomarkers for Prostate Cancer Detection and Risk Stratification

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2022 Jun 20

PMID 35719272

Authors

Mark W Farha

Simpa S Salami

Affiliations

Soon will be listed here.

Abstract

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most patients do not die from the disease. Prostate specific antigen (PSA), the most widely used oncologic biomarker, has revolutionized screening and early detection, resulting in reduced proportion of patients presenting with advanced disease. However, given the inherent limitations of PSA, additional diagnostic and prognostic tools are needed to facilitate early detection and accurate risk stratification of disease. Serum, urine, and tissue-based biomarkers are increasingly being incorporated into the clinical care paradigm, but there is still a limited understanding of how to use them most effectively. In the current article, we review test characteristics and clinical performance data for both serum [4 K score, prostate health index (phi)] and urine [SelectMDx, ExoDx Prostate Intelliscore, MyProstateScore (MPS), and PCa antigen 3 (PCA3)] biomarkers to aid decisions regarding initial or repeat biopsies as well as tissue-based biomarkers (Confirm MDx, Decipher, Oncotype Dx, and Polaris) aimed at risk stratifying patients and identifying those patients most likely to benefit from treatment surveillance or monotherapy multi-modal therapy.

Citing Articles

Non-DRE Voided Urine Test to Diagnose Prostate Cancer: Updated Results.

Gomella P, Leong J, Gomella L, Tomar V, Teran H, Trabulsi E Diagnostics (Basel). 2025; 15(5).

PMID: 40075854 PMC: 11899178. DOI: 10.3390/diagnostics15050607.

Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.

Baek J, Shim Y, Gu M In Vivo. 2025; 39(2):819-823.

PMID: 40010986 PMC: 11884465. DOI: 10.21873/invivo.13884.

Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy.

Schott D, Pizon M, Drozdz S, Maurer I, Wurschi G, Pachmann K Int J Mol Sci. 2025; 26(4).

PMID: 40004014 PMC: 11855499. DOI: 10.3390/ijms26041548.

Prostate cancer risk biomarkers from large cohort and prospective metabolomics studies: A systematic review.

Lopez-Hernandez Y, Andres-Lacueva C, Wishart D, Torres-Calzada C, Martinez-Huelamo M, Almanza-Aguilera E Transl Oncol. 2024; 51:102196.

PMID: 39580963 PMC: 11625367. DOI: 10.1016/j.tranon.2024.102196.

Microfluidic Applications in Prostate Cancer Research.

Szewczyk K, Jiang L, Khawaja H, Miranti C, Zohar Y Micromachines (Basel). 2024; 15(10).

PMID: 39459070 PMC: 11509716. DOI: 10.3390/mi15101195.

References

Parekh D, Punnen S, Sjoberg D, Asroff S, Bailen J, Cochran J . A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2014; 68(3):464-70. DOI: 10.1016/j.eururo.2014.10.021. View

Carter H . Prostate cancers in men with low PSA levels--must we find them?. N Engl J Med. 2004; 350(22):2292-4. PMC: 3474980. DOI: 10.1056/NEJMe048003. View

Albala D, Kemeter M, Febbo P, Lu R, John V, Stoy D . Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score. Rev Urol. 2016; 18(3):123-132. PMC: 5102928. DOI: 10.3909/riu0725. View

Deras I, Aubin S, Blase A, Day J, Koo S, Partin A . PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179(4):1587-92. DOI: 10.1016/j.juro.2007.11.038. View

de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D . Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol. 2015; 194(1):65-72. PMC: 4696043. DOI: 10.1016/j.juro.2015.01.091. View

Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G . Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One. 2013; 8(7):e67687. PMC: 3701535. DOI: 10.1371/journal.pone.0067687. View

Nam R, Saskin R, Lee Y, Liu Y, Law C, Klotz L . Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010; 183(3):963-8. DOI: 10.1016/j.juro.2009.11.043. View

Spratt D, Zhang J, Santiago-Jimenez M, Dess R, Davis J, Den R . Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2017; 36(6):581-590. PMC: 6530900. DOI: 10.1200/JCO.2017.74.2940. View

10.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

11.

Tosoian J, Trock B, Morgan T, Salami S, Tomlins S, Spratt D . Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. J Urol. 2020; 205(3):732-739. PMC: 8189629. DOI: 10.1097/JU.0000000000001430. View

12.

Freedland S, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J . Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86(5):848-53. PMC: 3710548. DOI: 10.1016/j.ijrobp.2013.04.043. View

13.

Kaul S, Wojno K, Stone S, Evans B, Bernhisel R, Meek S . Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019; 16(6):491-499. PMC: 7447833. DOI: 10.2217/pme-2019-0084. View

14.

Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N . The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015; 19(87):i-xxxi, 1-191. PMC: 4780983. DOI: 10.3310/hta19870. View

15.

Chai H, Brown R . Field effect in cancer-an update. Ann Clin Lab Sci. 2009; 39(4):331-7. View

16.

Maggi M, Del Giudice F, Falagario U, Cocci A, Russo G, DI Mauro M . SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers (Basel). 2021; 13(9). PMC: 8122883. DOI: 10.3390/cancers13092047. View

17.

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J . Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2007; 19(2):175-81. PMC: 3064270. DOI: 10.1007/s10552-007-9083-8. View

18.

Westphalen A, McCulloch C, Anaokar J, Arora S, Barashi N, Barentsz J . Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020; 296(1):76-84. PMC: 7373346. DOI: 10.1148/radiol.2020190646. View

19.

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

20.

Punnen S, Freedland S, Polascik T, Loeb S, Risk M, Savage S . A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. J Urol. 2017; 199(6):1459-1463. DOI: 10.1016/j.juro.2017.11.113. View